Granulocyte and monocytes, which form leukocytes that fight against diseases in the bone marrow, form young (blast) cells in the bone marrow. These cells mature over time and play an important role in the immune system.

As a result of the abnormality seen in the maturation of young cells in the findings of acute myeloblastic leukemia, it cannot fulfill its duty in the immune system with the collection of cells that cannot maintain their normal course in the blood and bone marrow. This clinical finding is called “Acute Myeloblastic Leukemia”.

• Chemotherapy
• It is done as a bone marrow (stem cell) transplant.

The building blocks of leukocytes in the body that play a role in the immune system are lymphocytes. These lymphocytes are referred to as lymphoblast when they are young in the bone marrow. It is a disease formed by the uncontrolled, abnormal and irregular proliferation of lymphoblasts in the bone marrow without maturation, and the inability to form lymphocytes, the mature cell.

• Chemotherapy
• Bone marrow (stem cell) transplant

• Leaching treatment
• Bone marrow (stem cell) transplant in resistant cases

Leukocytes that make up the immune system have more than normal mature cells in the blood. In this type of cancer, where genetic factors are effective (philadelphia chromosome), white blood cells are outnumbered from red blood cells and blood flakes.

It is a type of cancer that occurs by disrupting the structure of lymphocytes in the immune system and by numerous accumulation in the body. Structured lymphocytes cannot help the immune system, but also prevent the production of red blood cells and blood pulses.

• Chemotherapy and immunotherapy
• Radiotherapy if necessary
• Bone marrow (stem cell) transplant if necessary

Leukemia is diagnosed with a good patient history and physical examination. The patient generally applies to the doctor in a sluggish, exhausted, pale, fiery, lymph nodes grown, bruises on his body, liver and spleen grown.

After the examination, a complete blood count and peripheral spreading test are performed. In the peripheral smear test, blood cells are examined under the microcope. These tests are diagnosed with leukemia if there is an abnormal blood cell.

However, since leukemia is a cancer caused by the bone marrow, the exact diagnosis is made by the examination of the bone marrow in the laboratory of pathology, genetics and current cytometry.

• Peripheral smear
• Bone marrow aspiration and bone marrow biopsy if necessary
• Flow cytometry
• Genetic tests

• Blood count
• Peripheral smear
• Bone marrow aspiration and biopsy if necessary
• Flow cytometry
• Genetic tests

• Blood count
• Peripheral smear
• Bone marrow aspiration and biopsy
• Genetic tests

• Blood count
• Peripheral smear
• Flow cytometry
• Bone marrow aspiration and biopsy
• Genetic tests

Risk grouping of the disease is performed after diagnosis of leukemia. High-risk patients are given more intensive and longer, and some patients are treated with less intensity.

Treatment of leukemia is done primarily with chemotherapy drugs given from the vessel path and mouth. Chemotherapy can also be given to the cerebrospinal fluid to maintain the central nervous system or prevent its growth if damaged.

It is effective in increasing the chances of success of blood and blood products given in addition to chemotherapy, and preventive and therapeutic antimicrobial therapy when necessary, and treatments that support morale and mental health.

In addition, cancer drugs (immunotherapy) and radiotherapy that strengthen the immune system are used according to the patient’s condition.

Leukemia is a treatment model administered after very high dose chemotherapy in high-risk or recurrent lymphoma and solid tumors that are sensitive to chemotherapy.

The bone marrow or stem cell used for transplantation can be the patient’s own (autologist), as the tissue group is preferred in leukemias, from a suitable donor (allogenic).

Today, if the patient’s brother, mother, father and age are older, bone marrow can be transported with stem cells from their children. In this method called haploidentical transplant, incompatible tissues in the stem cell taken are extracted.

Although haploidentic bone marrow transplant has more risks than other types of transplants, these risks are approaching fully compatible transplants thanks to recent technological advances.

Due to the very high dose of chemotherapy administered prior to Bone Marrow Transplant, very important side effects such as tissue rejection, bleeding, infection may develop during transplantation and during the time the tissue is accepted. Although bone marrow transplant is a treatment model that increases the chances of the disease to heal, there is a risk of recurrence of the disease.

In the most common acute leukemias, the treatability rate can increase from 45 percent to 85 percent to vary depending on the cell type and the risk group of the disease. Leukemia is likely to recur in the remaining patients.

There is also a possibility that childhood cancer will recur in adulthood. This rate is less in leukemias and more in some brain tumors and solid tumors. If the disease is caught in the early stage and diagnosed and treated without metastasis, the probability of recurrence is reduced.

Leukemies are monitored for 10 years after treatment. Controls are carried out every month, then 3 months and annual periods. Over the years, the probability of recurrence decreases. Although it is very rare, there are patients who recur after 10 years.

As the molecular genetic characters of the leukemia cell are determined by ongoing research, new targeted treatment models are being developed. Today, according to the type and risk group of leukemia, patients can get their health with a treatment that lasts 2-3 years.

Although it does not respond or respond to the first treatment, then there is a chance to recover in some patients with bone marrow transplant therapy in recurrent disease.